2013 Philip S. Portoghese medicinal chemistry lectureship: Drug discovery targeting allosteric sites

Journal of Medicinal Chemistry

Volumn 57, Issue 18, 2014, Pages 7485-7498

  Lindsley, Craig W ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

G PROTEIN COUPLED RECEPTOR; PHOSPHOLIPASE D; PROTEIN KINASE B;

BINDING SITE; DRUG DEVELOPMENT; DRUG TARGETING; MODULATION; REVIEW; STRUCTURE ACTIVITY RELATION; ANIMAL; CHEMISTRY; HUMAN; METABOLISM; PROCEDURES;

ALLOSTERIC SITE; ANIMALS; DRUG DISCOVERY; HUMANS; PHOSPHOLIPASE D; PROTO-ONCOGENE PROTEINS C-AKT;

EID: 84907457165     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm5011786     Document Type: Review

References (92)

1. Lindsley, C. W. Adventures in allosteric drug discovery. Presented at the 246th National Meeting of the American Chemical Society, Indianapolis, IN, September 10, 2013; The 2013 Portoghese Lectureship
2. Lindsley, C. W. Adventures in allosteric drug discovery. Presented at the 246th National Meeting of the American Chemical Society, Indianapolis, IN, September 10, 2013; The 2013 Portoghese Lectureship.
3. Kenakin, T.; Miller, L. J. Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery Pharmacol. Rev. 2010, 62, 265-304
4. Fenton, A. W. Allostery: an illustrated definition for the "second secret of life" Trends Biochem. Sci. 2008, 33, 420-425
5. Conn, P. J.; Christopolous, A.; Lindsley, C. W. Allosteric modulators of GPCRs as a novel approach to treatment of CNS disorders Nat. Rev. Drug Discovery 2009, 8, 41-54
6. Bridges, T. M.; Lindsley, C. W. G-protein coupled receptors: from classical modes of modulation to allosteric mechanisms ACS Chem. Biol. 2008, 3, 530-542
7. Christopoulos, A.; Kenakin, T. G protein-coupled receptors allosterism and complexing Pharmacol. Rev. 2002, 54, 323-374
8. Christopoulos, A. Allosteric binding sites on cell surface receptors: novel targets for drug discovery Nat. Rev. Drug Discovery 2002, 1, 198-210
9. Kenakin, T. P. 7TM receptor allostery: putting numbers to shapeshifting proteins Trends Pharmacol. Sci. 2009, 30, 460-469
10. Lane, R. J.; Abdul-Ridha, A.; Canals, M. Regulation of G protein-coupled receptors by allosteric ligands ACS Chem. Neurosci. 2013, 4, 527-534
11. Monod, J.; Wyman, J.; Changeux, J.-P. On the nature of allosteric transitions: a plausible model J. Mol. Biol. 1956, 88-118
12. Melancon, B. J.; Hopkins, C. R.; Wood, M. R.; Emmitte, K. A.; Niswender, C. M.; Christopoulos, A.; Conn, P. J.; Lindsley, C. W. Allosteric modulation of 7 transmembrane spanning receptors: theory, practice and opportunities for CNS drug discovery J. Med. Chem. 2012, 55, 1445-1464
13. Conn, P. J.; Lindsley, C. W.; Meiler, J.; Niswender, C. M. Opportunities and challenges in discovery of allosteric modulators of GPCRs for treatment of CNS disorders Nat. Rev. Drug Discovery 2014, 13, 692-708
14. Mohler, H. F.; Fritschy, J. M.; Rudolph, U. A new benzodiazepine pharmacology J. Pharmacol. Exp. Ther. 2002, 300, 2-8
15. Wenthur, C. J.; Gentry, P. R.; Matthews, T. P.; Lindsley, C. W. Drugs for allosteric sites on receptors Annu. Rev. Pharmacol. Toxicol. 2014, 54, 165-184
16. Nemeth, E. F.; Heaton, W. H.; Miller, M.; Fox, J.; Balandrin, M. F.; Van Wagenen, B. C.; Colloton, M.; Karbon, W.; Scherrer, J.; Shatzen, E.; Rishton, G.; Scully, S.; Qi, M.; Harris, R.; Lacey, D.; Martin, D. Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl J. Pharmacol. Exp. Ther. 2004, 308, 627-635
17. Meanwell, N. A.; Kadow, J. F. Maraviroc, a chemokine CCR5 receptor antagonist for the treatment of HIV infection and AIDS Curr. Opin. Invest. Drugs 2007, 8, 669-681
18. For information on the VCNDD, see the following: http://www.vcndd.com/ (accessed August 1, 2014).
19. For information on the MLPCN and available probe compounds, see the following: https://mli.nih.gov/mli/mlpcn/ (accessed August 1, 2014).
20. Johnson, L. N.; Lewis, R. J. Structural basis for control by phosphorylation Chem. Rev. 2001, 101, 2209-2242
21. Pawson, T.; Scott, J. D. Protein phosphorylation in signaling Trends Biochem. Sci. 2005, 30, 286-290
22. Cohen, P. Protein kinases-the major drug targets of the twenty-first century? Nat. Rev. Drug Discovery 2002, 1, 309-315
23. Zheng, J.; Eyck, L.; Karlsson, R.; Xuong, N.; Taylor, S. S.; Sowadski, J. M. Crystal structure of the catalytic subunit of cAMP-dependent protein kinase complexed with MgATP and peptide inhibitor Biochemistry 1993, 32, 2154-2161
24. Hantschel, O. Structure, regulation, signaling, and targeting of Abl kinases in cancer Genes Cancer 2012, 3, 436-446
25. Palmieri, L.; Giulio, R. αC Helix displacement as a general approach for allosteric modulation of protein kinases Drug Discovery Today 2012, 1-8
26. Betzi, S.; Riazul, A.; Mathew, M.; Lubbers, D. J.; Han, H.; Jakkaraj, S. R.; Georg, G. I.; Schönbrunn, E. Discovery of a potential allosteric ligand binding site in CDK2 ACS Chem. Biol. 2011, 6, 492-501
27. Busschots, K.; Lopez-Garcia, L. A.; Lammi, C.; Stroba, A.; Zeuzem, S.; Piiper, A.; Alzari, P. M.; Neimanis, S.; Arencibia, J. M.; Engel, M.; Schulze, J. O.; Biondi, R. M. Substrate-selective inhibition of protein kinase PDK1 by small compounds that bind to the PIF-pocket allosteric docking site Chem. Biol. 2012, 19, 1152-1163
28. Lopez-Garcia, L.; Schulze, J. O.; Fröhner, W.; Zhang, H.; Süss, E.; Weber, N.; Navratil, J.; Amon, S.; Hindie, V.; Zeuzem, S.; Jorgensen, T. J. D.; Alzari, P. M.; Engel, M.; Biondi, R. M. Allosteric regulation of protein kinase PKCΧ by the N-terminal C1 domain and small compounds to the PIF-pocket Chem. Biol. 2011, 18, 1463-1473
29. Fischmann, T. O.; Smith, C. K.; Mayhood, T. W.; Myers, J. E.; Reichert, P.; Mannarino, A.; Carr, D.; Zhu, H.; Wong, J.; Yang, R.-S.; Le, H. V.; Madison, V. S. Crystal structures of MEK1 binary and ternary complexes with nucleotides and inhibitors Biochemistry 2009, 48, 2661-2674
30. Fang, Z.; Christian, G.; Daniel, R. Strategies for the selective regulation of kinases with allosteric modulators: exploiting exclusive structural features ACS Chem. Biol. 2013, 8, 58-70
31. Hennessy, B. T.; Smith, D. L.; Ram, P. T.; Lu, Y.; Mills, G. B. Exploiting the PI3K/AKT pathway for cancer drug discovery Nat. Rev. Drug Discovery 2005, 4, 988-1004
32. Barnett, S. F.; Bilodeau, M. T.; Lindsley, C. W. The Akt/PKB family of protein kinases: a review of small molecule inhibitors and progress towards target validation Curr. Top. Med. Chem. 2005, 5, 109-125
33. Lindsley, C. W. The Akt/PKB family of protein kinases: a review of small molecule inhibitors and progress towards target validation: a 2009 update Curr. Top. Med. Chem. 2010, 10, 458-477
34. Kumar, C.; Madison, V. AKT crystal structure and AKT-specific inhibitors Oncogene 2005, 24, 7493-7501
35. Cheng, J. Q.; Lindsley, C. W.; Cheng, G. Z.; Yang, H.; Nicosia, S. V. The Akt/PKB pathway: molecular target for cancer drug discovery Oncogene 2005, 24, 7482-7492
36. Kim, D.; Cheng, G. Z.; Lindsley, C. W.; Yang, H.; Cheng, J. Q. Targeting phosphatidylinositol-3 kinase/Akt pathway for cancer therapy Curr. Opin. Invest. Drugs 2005, 6, 1250-1258
37. Lindsley, C. W.; Zhao, Z.; Duggan, M. E.; Barnett, S. F.; Defeo-Jones, D.; Huber, H. E.; Huff, J. R.; Hartman, G. D.; Leister, W.; Kral, A.; Fu, S.; Hancock, P. J.; Haskell, K. A.; Jones, R. E.; Robinson, R. Allosteric Akt (PKB) kinase inhibitors. Discovery and SAR of isozyme selective inhibitors Bioorg. Med. Chem. Lett. 2005, 15, 761-764
38. Defeo-Jones, D.; Barnett, S. F.; Fu, S.; Hancock, P. J.; Haskell, K. M.; Leander, K. R.; McAvoy, E.; Lindsley, C. W.; Duggan, M. E.; Hartman, G. D.; Huber, H. E. Tumor cell sensitization to apoptotic stimuli by selective inhibition of specific Akt/PKB family members Mol. Cancer Ther. 2005, 4, 271-279
39. Barnett, S. F.; Defeo-Jones, D.; Fu, S.; Hancock, P. J.; Haskell, K. M.; Jones, R. E.; Kahana, J. A.; Kral, A. M.; Leander, K.; Lee, L. L.; Malinowski, J.; McAvoy, E. M.; Nahas, D. D.; Robinson, R. G.; Huber, H. E. Identification and characterization of pleckstin-homology-domain-dependent and isoenzyme-specfic Akt inhibitors Biochem. J. 2005, 385, 399-408
40. Kennedy, J. P.; Williams, L.; Bridges, T. M.; Daniels, R. N.; Weaver, C. D.; Lindsley, C. W. Application of combinatorial chemistry science on modern drug discovery J. Comb. Chem. 2008, 10, 345-354
41. Hirai, H.; Sootome, H.; Nakatsuru, Y.; Miyama, K.; Taguchi, S.; Tsukioka, K.; Ueno, Y.; Hatch, H.; Majumder, P. K.; Pan, B.-S.; Kotani, H. MK-2206, an allosteric Akt inhibitor, enhances tumor efficacy by standard chemotherapetuic agents or molecular targetd drugs in vitro and in vivo Mol. Cancer Ther. 2010, 9, 1956-1967
42. Calleja, V.; Laguerre, M.; Larijani, B. Role of a novel PH-kinase domain interface in PKB/Akt regulation: structural mechanism for allosteric inhibition PLoS Biol. 2009, 7, 189-200
43. Okuzumi, T.; Fielder, D.; Zhang, C.; Gray, D. C.; Aizenstein, B.; Hoffman, R.; Shokat, K. M. Inhibitor hijacking of Akt activation Nat. Chem. Biol. 2009, 5, 484-493
44. Niswender, C. M.; Conn, P. J. Metabotropic glutamate receptors: physiology, pharmacology and disease Annu. Rev. Pharmacol. Toxicol. 2010, 50, 295-322
45. 5ACS Chem. Neurosci. 2011, 2, 411-432
46. Lindsley, C. W.; Shipe, W. D.; Wolkenberg, S. E.; Theberge, C. R.; Williams, D. L., Jr.; Sur, C.; Kinney, G. G. Progress towards validating the NMDA receptor hypofunction hypothesis of schizophrenia Curr. Top. Med. Chem. 2006, 6, 771-785
47. O'Brien, J. A.; Lemaire, W.; Chen, T. B.; Chang, R. S. L.; Jacobson, M. A.; Ha, S. N.; Lindsley, C. W.; Schaffhauser, H. J.; Sur, C.; Pettibone, D. J.; Conn, P. J.; Williams, D. L., Jr. A family of highly selectiveallosteric modulators of the metabotropic glutamate receptor subtype 5 Mol. Pharmacol. 2003, 64, 731-740
48. Sharma, S.; Rodriguez, A. L.; Conn, P. J.; Lindsley, C. W. Synthesis and SAR of a mGluR5 allosteric partial antagonist lead: unexpected modulation of pharmacology with slight structural modifications to a 5-(phenylethynyl)pyrimidine scaffold Bioorg. Med. Chem. Lett. 2008, 18, 4098-5101
49. Sharma, S.; Kedrowski, J.; Rodriguez, A. L.; Niswender, C. M.; Jones, C. K.; Conn, P. J.; Lindsley, C. W. Discovery of molecular switches that modulate modes of mGlu5 pharmacology in vitro and in vivo within a series of functionalized, regioisomeric 2- and 5-(phenylethynyl)pyrimidines J. Med. Chem. 2009, 52, 4103-4106
50. Wood, M. R.; Hopkins, C. R.; Brogan, J. T.; Conn, P. J.; Lindsley, C. W. "Molecular Switches" on mGluR allosteric ligands that modulate modes of pharmacology Biochemistry 2011, 50, 2403-2410
51. O'Brien, J. A.; Lemaire, W.; Wittmann, M.; Jacobson, M. A.; Ha, S. N.; Wisnoski, D. D.; Lindsley, C. W.; Schaffhauser, H. J.; Rowe, B.; Sur, C.; Williams, D. L., Jr.; Conn, P. J. A novel selective allosteric modulator potentiates the activity of native metabotropic glutamate receptor subtype 5 in rat forebrain J. Pharmacol. Exp. Ther. 2004, 309, 568-577
52. Zhao, Z.; Wisnoski, D. D.; Lemaire, W.; O'Brien, J. A.; Williams, D. L., Jr.; Jacobson, M. A.; Lindsley, C. W. Challenges in the development of mGluR5 positive allosteric modulators: the discovery of CPPHA Bioorg. Med. Chem. Lett. 2007, 17, 1386-1391
53. Lindsley, C. W.; Wisnoski, D. D.; Duggan, M. E.; Leister, W. H.; Hartman, G. D.; Huff, J. R.; Williams, D. L., Jr.; O'Brien, J. A.; Lemaire, W.; Sur, C.; Kinney, G. G.; Conn, P. J.; Duggan, M. E. Discovery of positive allosteric modulators for the metabotropic glutamate receptor subtype 5 (mGluR5) that potentiate receptor function in vivo J. Med. Chem. 2004, 47, 5825-5828
54. Kinney, G. G.; O'Brien, J. A.; Lemaire, W.; Burno, M.; Bickel, D. J.; Clements, M. K.; Chen, T. B.; Wisnoski, D. D.; Lindsley, C. W.; Tiller, P. R.; Conn, P. J.; Williams, D. L., Jr. A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models J. Pharmacol. Exp. Ther. 2005, 313, 199-206
55. 5) ACS Chem. Neurosci. 2011, 2, 450-470
56. Parmentier-Batteur, S.; Hutson, P. H.; Menzel, K.; Uslaner, J. M.; Mattson, B. A.; O'Brien, J. A.; Magliaro, B. C.; Forest, T.; Stump, C. A.; Tynebor, R. M.; Anthony, N. J.; Tucker, T. J.; Zhang, X. F.; Gomez, R.; Huszar, S. L.; Lambeng, N.; Fauré, H.; Le Poul, E.; Poli, S.; Rosahl, T. W.; Rocher, J. P.; Hargreaves, R.; Williams, T. M. Mechanism based neurotoxicity of mGlu5 positive allosteric modulators: development challenges for a promising novel antipsychotic target Neuropharmacology 2014, 82, 161-173
57. Bridges, T. M.; Rook, J. R.; Noetzel, M. J.; Morrison, R. D.; Zhou, Y.; Gogliotti, R. D.; Vinson, P. N.; Xiang, Z.; Jones, C. K.; Niswender, C. M.; Lindsley, C. W.; Stauffer, S. R.; Conn, P. J.; Daniels, S. J. Biotransformation of a novel positive allosteric modulator of metabotropic glutamate receptor subtype 5 contributes to seizure-like adverse events in rats involving a receptor agonism-dependent mechanism Drug Metab. Dispos. 2013, 41, 1703-1714
58. Rook, J. M.; Noetzel, M. J.; Pouliot, W. A.; Bridges, T. M.; Vinson, P. N.; Cho, H. P.; Zhou, Y.; Stauffer, S. R.; Niswender, C. M.; Daniels, S. J.; Lindsley, C. W.; Conn, P. J. Unique signaling profiles of positive allosteric modulators of metabotropic mlutamate receptor subtype 5 determine differences in in vivo activity Biol. Psychiatry 2013, 73, 501-509
59. Schann, S.; Mayer, S.; Franchet, C.; Frauli, M.; Steinberg, E.; Thomas, M.; Baron, L.; Neuville, P. Chemical switch of a metabotropic glutamate receptor 2 silent sllosteric modulator into dual metabotropic glutamate receptor 2/3 negative/positive allosteric modulators J. Med. Chem. 2010, 53, 8775-8779
60. Utley, T.; Haddenham, D.; Salovich, J. M.; Zamorano, R.; Vinson, P. N.; Lindsley, C. W.; Hopkins, C. R.; Niswender, C. M. Synthesis and SAR of a novel metabotropic glutamate receptor 4 (mGlu4) antagonist: unexpected "molecular switch" from a closely related mGlu4 positive allosteric modulator Bioorg. Med. Chem. Lett. 2011, 21, 6955-6959
61. Digby, G. J.; Utley, T. J.; Lamsal, A.; Sevel, C.; Sheffler, D. J.; Lebois, E. P.; Bridges, T. M.; Lindsley, C. W.; Conn, P. J. Chemical modification of the M(1) agonist VU0364572 reveals molecular switches in pharmacology and a bitopic binding mode ACS Chem. Neurosci. 2012, 3, 1025-1036
62. Luker, T.; Bonnert, R.; Schmidt, R.; Sargent, C.; Paine, S. W.; Thom, S.; Pairaudeau, G.; Patel, A.; Mohammed, R.; Akam, E.; Dougall, I.; Davis, A. M.; Abbott, S.; Millichip, I.; McInally, T. Switching between agonists and antagonists at CRTh2 in a series of highly potent and selective biaryl phenoxyacetic acids Bioorg. Med. Chem. Lett. 2011, 21, 3616-3621
63. Cheung, Y. Y.; Haibo, Yu.; Kaiping, Xu.; Beiyan, Zou; Lindsley, C. W.; Li, M.; Hopkins, C. R. Discovery of a series of 2-phenyl- N -(2-(pyrrolidin-1-yl) phenyl) acetamides as novel molecular switches that modulate modes of Kv7. 2 (KCNQ2) channel J. Med. Chem. 2012, 55, 6975-6979
64. Gregory, K. J.; Noetzel, M. J.; Rook, J. M.; Vinson, P. N.; Stauffer, S. R.; Rodriguez, A. L.; Emmitte, K. A.; Niswender, C. M.; Lindsley, C. W.; Conn, P. J. Investigating metabotropic glutamate receptor 5 allosteric modulator cooperativity, affinity, and agonism: enriching structure-function studies and structure-activity relationships Mol. Pharmacol. 2012, 82, 860-875
65. 5PAM Bioorg. Med. Chem. Lett. 2012, 22, 3921-3925
66. 3selective and CNS penetrant negative allosteric modulator (NAM) J. Med. Chem. 2013, 56, 5308-5212
67. Notartomaso, S.; Zappulla, C.; Biagioni, F.; Cannella, M.; Bucci, D.; Mascio, G.; Scarselli, P.; Fazio, F.; Weisz, F.; Lionetto, L.; Simmaco, M.; Gradini, R.; Battaglia, G.; Signore, M.; Puliti, A.; Nicoletti, F. Pharmacological enhancement of mGlu1 metabotropic glutamate receptors causes a prolonged symptomatic benefit in a mouse model of spinocerebellar ataxia type 1 Mol. Brain 2013, 19, 1650-1666
68. Williams, R.; Zhou, Y.; Niswender, C. M.; Luo, Q.; Conn, P. J.; Lindsley, C. W.; Hopkins, C. R. Re-exploration of the PHCCC scaffold: discovery of improved positive allosteric modulators of mGlu4 ACS Chem. Neurosci. 2010, 1, 411-419
69. 4) with oral efficacy in an antiparkinsonian animal model J. Med. Chem. 2011, 54, 7639-7647
70. Cho, H. P.; Engers, D. W.; Venable, D. F.; Niswender, C. M.; Lindsley, C. W.; Conn, P. J.; Emmitte, K. A.; Rodriguez, A. L. A novel class of succinimide-derived negative allosteric modulators of metabotropic glutamate receptor subtype 1 provides insight into a disconnect in activity between the rat and human receptors ACS Chem. Neurosci. 2014, 5, 597-610
71. Cho, H. P.; Garcia-Barrantes, P. M.; Brogan, J. T.; Hopkins, C. R.; Niswender, C. M.; Rodriguez, A. L.; Venable, D.; Morriosn, R. D.; Bubser, M.; Daniels, S. J.; Jones, C. K.; Conn, P. J.; Lindsley, C. W. Chemical modulation of mutant mGlu1receptors derived from deleterious GRM1 mutations found in schizophrenics: development of novel mGlu1 PAMs via a "double molecular switch" of an mGlu4 PAM chemotype ACS Chem. Biol. 2014, 10.1021/cb500560h
72. Bridges, T. M.; Marlo, J. E.; Niswender, C. M.; Jones, C. K.; Jahhav, S. B.; Gentry, P. R.; Cho, H. P.; Weaver, C. D.; Conn, P. J.; Lindsley, C. W. Discovery of the first highly M5-preferring muscarinic acetylcholine receptor ligand, an M5 positive allosteric modulator derived from a series of 5-trifluoromethoxy N -benzyl isatins J. Med. Chem. 2009, 52, 3445-3448
73. Bridges, T. M.; Kennedy, J. P.; Noetzel, M. J.; Breininger, M. L.; Gentry, P. R.; Conn, P. J.; Lindsley, C. W. Chemical lead optimization of a Ppan Gq mAChR M1, M3, M5 positive allosteric modulator (PAM) lead. Part II: Development of a potent and highly selective M1 PAM Bioorg. Med. Chem. Lett. 2010, 20, 1972-1975
74. Mirza, N. R.; Peters, D.; Sparks, R. G. Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists CNS Drug Rev. 2003, 9, 159-186
75. 1muscarinic acetylcholine receptor regulates amyloid processing and produces antipsychotic-like activity in rats J. Neurosci. 2008, 28, 10422-10433
76. 1receptor function in the central nervous system ACS Chem. Neurosci. 2010, 1, 104-121
77. 1allosteric agonism and result in pan-mAChR orthosteric antagonism Bioorg. Med. Chem. Lett. 2013, 23, 223-227
78. 1muscarinic acetylcholine receptors induce brain region-specific responses that correspond with behavioral effects in animal models J. Neurosci. 2012, 32, 8532-8544
79. Ma, L.; Seager, M. A.; Wittmann, M.; Jacobson, M.; Bickel, D.; Burno, M.; Jones, K.; Graufelds, V. K.; Xu, G.; Pearson, M.; McCampbell, A.; Gaspar, R.; Shughrue, P.; Danziger, A.; Regan, C.; Flick, R.; Pascarella, D.; Garson, S.; Doran, S.; Kreatsoulas, C.; Veng, L.; Lindsley, C. W.; Shipe, W.; Kuduk, S.; Sur, C.; Kinney, G.; Seabrook, G. R.; Ray, W. J. Selective activation of the M1 muscarinic acetylcholine receptor achieved by allosteric potentiation Proc. Natl. Acad. Sci. U.S.A. 2009, 106, 15950-15955
80. 1positive allosteric modulator ML169 ACS Chem. Neurosci. 2012, 3, 884-895
81. Byun, N. E.; Grannan, M.; Bubser, M.; Barry, R. L.; Thompson, A.; Rosanelli, J.; Gowrishankar, R.; Kelm, N. D.; Damon, S.; Bridges, T. M.; Melancon, B. J.; Tarr, J. C.; Brogan, J. T.; Avison, M. J.; Deutch, A. Y.; Wess, J.; Wood, M. R.; Lindsley, C. W.; Gore, J. C.; Conn, P. J.; Jones, C. K. Antipsychotic drug-like effects of the selective M4 muscarinic acetylcholine receptor positive allosteric modulator VU0152100 Neuropsychopharmacology 2014, 39, 1578-1593
82. Bubser, M.; Bridges, T. M.; Dencker, D.; Gould, R. W.; Grannan, M. D.; Wes, J.; Duggan, M. E.; Dunlop, J.; Wood, M. R.; Lindsley, C. W.; Conn, P. J.; Jones, C. K. Selective activation of M4 muscarinic acetylcholine receptors reverses MK-801-induced behavioral impairments and enhances associative learning in rodents ACS Chem. Neurosci. 2014, 10.1021/cn500128b
83. Dore, A. S.; Okrasa, K.; Patel, J. C.; Serrano-Vega, M.; Bennett, K.; Cooke, R. M.; Errey, J. C.; Jazayeri, A.; Khan, S.; Tehan, B.; Weir, M.; Wiggin, G. R.; Marshall, F. H. Structure of class C GPCR metabotropic glutamate receptor 5 transmembrane domain Nature 2014, 511, 557-562
84. Selvy, P. E.; Lavieri, R.; Lindsley, C. W.; Brown, H. A. Phospholipase D: enzymology, signaling, and chemical modulation Chem. Rev. 2011, 111, 6064-6119
85. Monovich, L.; Mugrage, B.; Quadros, E.; Toscano, K.; Tommasi, R.; LaVoie, S.; Liu, E.; Du, Z. M.; LaSala, D.; Boyar, W.; Steed, P. Optimization of halopemide for phospholipase D2 inhibition Bioorg. Med. Chem. Lett. 2007, 17, 2310-2311
86. De Cuyper, H.; Verstraeten, D. The clinical significance of halpemide, a dopamine-blocker related to butyrphenones Neuropsychobiology 1984, 12, 211-216
87. Scott, S. A.; Selvy, P. E.; Buck, J.; Cho, H. P.; Criswell, T. L.; Thomas, A. L.; Armstrong, M. D.; Arteaga, C.; Lindsley, C. W.; Brown, H. A. Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness Nat. Chem. Biol. 2009, 5, 108-117
88. Lewis, J. A.; Scott, S. A.; Lavieri, R.; Buck, J. R.; Selvy, P. E.; Stoops, S. L.; Armstrong, M. D.; Brown, H. A.; Lindsley, C. W. Design and synthesis of isoform-selective phospholipase D (PLD) inhibitors. Part I: Impact of alternative halogenated privileged structures on PLD1 specificity Bioorg. Med. Chem. Lett. 2009, 19, 1916-1919
89. Lavieri, R.; Scott, S. A.; Selvy, P. E.; Brown, H. A.; Lindsley, C. W. Design, synthesis and biological evaluation of halogenated N -(2-(4-oxo-1-phenyl-1,3,8-triazasprio[4.5]decan-8-yl)ethylbenzamides: discovery of an isoform selective small-molecule phospholipase D2 (PLD2) inhibitor J. Med. Chem. 2010, 53, 6706-6719
90. O'Reilly, M. C.; Scott, S. A.; Brown, K. A.; Oquin, T. H., III; Thomas, P. G.; Daniels, J. S.; Morrison, R.; Brown, H. A.; Lindsley, C. W. Development of dual PLD1/2 and PLD2 selective inhibitors from a common 1,3,8-triazaspiro[4.5]decane core; discovery of ML298 and ML299 that decrease invasive migration in U87-MG glioblastoma cells J. Med. Chem. 2013, 56, 2695-2699
91. 2mediates survival signaling through direct regulation of Akt in glioblastoma cells J. Biol. Chem. 2014, 289, 600-616
92. Oguin, T.; Sharma, S.; Stuart, A. D.; Jones, C. K.; Daniels, J. S.; Lindsley, C. W.; Thomas, P. G.; Brown, H. A. Phospholipase D facilitates efficient entry of influenza virus allowing escape from innate mmune inhibition J. Biol. Chem. 2014, 10.1074/jbc.M114.558817